DrugPatentWatch Database Preview
Rubicon Company Profile
What is the competitive landscape for RUBICON, and what generic and branded alternatives to RUBICON drugs are available?
RUBICON has nineteen approved drugs.
Summary for Rubicon
| US Patents: | 0 |
| Tradenames: | 17 |
| Ingredients: | 17 |
| NDAs: | 19 |
Drugs and US Patents for Rubicon
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rubicon | CARVEDILOL | carvedilol | TABLET;ORAL | 078165-004 | Sep 5, 2007 | AB | RX | No | No | Start Trial | Start Trial | ||||
| Rubicon | BACLOFEN | baclofen | TABLET;ORAL | 209102-001 | Nov 28, 2017 | RX | No | No | Start Trial | Start Trial | |||||
| Rubicon | PANTOPRAZOLE SODIUM | pantoprazole sodium | TABLET, DELAYED RELEASE;ORAL | 090807-001 | May 2, 2012 | AB | RX | No | No | Start Trial | Start Trial | ||||
| Rubicon | SILDENAFIL CITRATE | sildenafil citrate | TABLET;ORAL | 204882-002 | Jun 11, 2018 | AB | RX | No | No | Start Trial | Start Trial | ||||
| Rubicon | SILDENAFIL CITRATE | sildenafil citrate | TABLET;ORAL | 204882-003 | Jun 11, 2018 | AB | RX | No | No | Start Trial | Start Trial | ||||
| Rubicon | SILDENAFIL CITRATE | sildenafil citrate | TABLET;ORAL | 204882-001 | Jun 11, 2018 | AB | RX | No | No | Start Trial | Start Trial | ||||
| Rubicon | CARVEDILOL | carvedilol | TABLET;ORAL | 078165-001 | Sep 5, 2007 | AB | RX | No | No | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
